clinical trial · NCT05521997
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Advanced Cervical CarcinomaCervical CancerCervix CancerCancer of the CervixTelaglenastatRadiation treatmentCisplatin
brief summary
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
started
Jul 31, 2026
primary completion
Oct 7, 2032
completion
Oct 7, 2032
last updated
Mar 13, 2026
official title
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol